EUDA Health Holdings Limited — News

SINGAPORE, July 30, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today provided important additional details of the integrated cell therapy program to be pursued under its recently announced non-binding Memorandum of Understanding (MOU) with GO POSB Organoids Pte Ltd ("GO POSB") and Shenzhen Innovation Immunotechnology Co.

globenewswire.com - 2026-07-30 06:00:00

SINGAPORE, July 30, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today provided important additional details of the integrated cell therapy program to be pursued under its recently announced non-binding Memorandum of Understanding (MOU) with GO POSB Organoids Pte Ltd (“GO POSB”) and Shenzhen Innovation Immunotechnology Co., Ltd. (“SIIT”).

globenewswire.com - 2026-07-30 06:00:00

SINGAPORE, July 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today announced that it has signed a Memorandum of Understanding ("MOU") with GO POSB Organoids Pte Ltd ("GO POSB") and Shenzhen Innovation Immunotechnology Co.

globenewswire.com - 2026-07-28 06:00:00

SINGAPORE, July 28, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) a Singapore-based distributor of third-party provided wellness and non-invasive healthcare products and services in Asia, with a focus on Singapore, Malaysia and China, today announced that it has signed a Memorandum of Understanding (“MOU”) with GO POSB Organoids Pte Ltd (“GO POSB”) and Shenzhen Innovation Immunotechnology Co., Ltd. (“SIIT”) to establish a tri-party collaboration with next-generation therapies derived from induced pluripotent stem cells (“iPSC”).

globenewswire.com - 2026-07-28 06:00:00

EUDA Health (NASDAQ: EUDA - Get Free Report) and Phreesia (NYSE: PHR - Get Free Report) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their analyst recommendations, dividends, profitability, valuation, earnings, institutional ownership and risk. Profitability This table compares EUDA Health and Phreesia's

defenseworld.net - 2026-07-28 01:15:18

SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) ("EUDA" or the "Company"), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced it is expanding the Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask ("Regenixé Mask"), a beauty product developed by Chemokine Pte Ltd ("Chemokine").

globenewswire.com - 2026-06-01 06:05:00

SINGAPORE, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (NASDAQ: EUDA) (“EUDA” or the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, today announced it is expanding the Helixé product line with the launch of the Regenixé iPSC-derived Skin Stem Cell Secretome Mask (“Regenixé Mask”), a beauty product developed by Chemokine Pte Ltd (“Chemokine”).

globenewswire.com - 2026-06-01 06:05:00

Singapore, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited ("EUDA" and the "Company"), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, received a written notice (the "MVLS Notice") from Listing Qualifications Department of The Nasdaq Stock Market ("Nasdaq") on April 23, 2026, indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities ("MVLS") of $35 million over the last 32 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2).

globenewswire.com - 2026-06-01 06:00:00

Singapore, June 01, 2026 (GLOBE NEWSWIRE) -- EUDA Health Holdings Limited (“EUDA” and the “Company”), a Singapore-based non-invasive healthcare provider in Asia with a focus on Singapore, Malaysia and China, received a written notice (the “MVLS Notice”) from Listing Qualifications Department of The Nasdaq Stock Market (“Nasdaq”) on April 23, 2026, indicating that the Company had failed to maintain a Minimum Market Value of Listed Securities (“MVLS”) of $35 million over the last 32 consecutive business days as required by the Nasdaq Listing Rule 5550(b)(2).

globenewswire.com - 2026-06-01 06:00:00